Mizuho reissued their buy rating on shares of Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) in a report issued on Monday morning. They currently have a $26.00 target price on the specialty pharmaceutical company’s stock.

Other equities analysts have also issued reports about the company. Credit Suisse Group AG reiterated a buy rating and set a $21.00 price objective on shares of Adamas Pharmaceuticals in a research report on Monday, July 25th. Noble Financial reiterated a buy rating and set a $25.00 price objective on shares of Adamas Pharmaceuticals in a research report on Friday, July 22nd. Needham & Company LLC reiterated a buy rating and set a $38.00 price objective on shares of Adamas Pharmaceuticals in a research report on Wednesday, July 20th. JMP Securities reiterated a buy rating on shares of Adamas Pharmaceuticals in a research report on Sunday. Finally, Zacks Investment Research upgraded Adamas Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, October 11th. One research analyst has rated the stock with a sell rating and nine have issued a buy rating to the stock. The company currently has an average rating of Buy and an average target price of $30.33.

Adamas Pharmaceuticals (NASDAQ:ADMS) opened at 15.69 on Monday. The firm’s market capitalization is $344.07 million. Adamas Pharmaceuticals has a 52 week low of $12.02 and a 52 week high of $31.84. The firm has a 50-day moving average price of $15.37 and a 200 day moving average price of $15.46.

Adamas Pharmaceuticals (NASDAQ:ADMS) last released its quarterly earnings results on Thursday, November 3rd. The specialty pharmaceutical company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.17. Adamas Pharmaceuticals had a negative return on equity of 38.31% and a negative net margin of 5,267.99%. The firm had revenue of $0.14 million for the quarter, compared to analysts’ expectations of $0.26 million. During the same quarter last year, the firm posted ($0.81) EPS. The company’s revenue was down 81.8% compared to the same quarter last year. On average, equities research analysts forecast that Adamas Pharmaceuticals will post ($3.06) earnings per share for the current fiscal year.

In other news, major shareholder Ix Lp Mdv acquired 62,977 shares of the business’s stock in a transaction that occurred on Friday, September 16th. The stock was bought at an average price of $16.48 per share, with a total value of $1,037,860.96. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director William W. Ericson acquired 60,846 shares of the business’s stock in a transaction that occurred on Wednesday, September 7th. The stock was purchased at an average cost of $15.68 per share, with a total value of $954,065.28. The disclosure for this purchase can be found here. 31.79% of the stock is owned by company insiders.

Hedge funds have recently modified their holdings of the company. Bow Street LLC purchased a new stake in shares of Adamas Pharmaceuticals during the second quarter valued at approximately $7,369,000. Brenner West Capital Advisors LLC raised its stake in shares of Adamas Pharmaceuticals by 87.2% in the second quarter. Brenner West Capital Advisors LLC now owns 1,017,000 shares of the specialty pharmaceutical company’s stock valued at $15,397,000 after buying an additional 473,762 shares during the last quarter. Granite Point Capital Management L.P. purchased a new stake in shares of Adamas Pharmaceuticals during the second quarter valued at approximately $3,396,000. Bingham Osborn & Scarborough LLC raised its stake in shares of Adamas Pharmaceuticals by 683.0% in the second quarter. Bingham Osborn & Scarborough LLC now owns 234,900 shares of the specialty pharmaceutical company’s stock valued at $3,556,000 after buying an additional 204,900 shares during the last quarter. Finally, Point72 Asset Management L.P. purchased a new stake in shares of Adamas Pharmaceuticals during the second quarter valued at approximately $2,176,000. 74.65% of the stock is owned by institutional investors.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). Its segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system.

5 Day Chart for NASDAQ:ADMS

Receive News & Stock Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.